Literature DB >> 10873874

Natural history of arteriovenous grafts in hemodialysis patients.

P E Miller1, D Carlton, M H Deierhoi, D T Redden, M Allon.   

Abstract

Most hemodialysis patients in the United States have an arteriovenous graft as their vascular access. Grafts have a relatively short life span and are prone to recurrent stenosis and thrombosis, requiring multiple salvage procedures to maintain their patency. There is little information in the literature regarding the clinical factors that determine graft survival and complications. We evaluated prospectively the outcomes of 256 grafts placed at a single institution during a 2-year period. A salvage procedure to maintain graft patency (thrombectomy, angioplasty, or surgical revision) was required in 29% of the grafts at 3 months, 52% at 6 months, 77% at 12 months, and 96% at 24 months. Thus, primary graft survival (time from graft placement to the first intervention) was only 23% at 1 year and 4% at 2 years. Primary graft survival was significantly less among patients with hypoalbuminemia compared with patients with a normal serum albumin level (P = 0.003). Secondary graft survival (time from graft placement to permanent graft failure) was 65% at 1 year and 51% at 2 years. Neither primary nor secondary graft survival was significantly correlated with patient age, sex, diabetic status, body mass index, or graft site. A mean of 1.22 interventions per graft-year were required to maintain access patency, including 0.51 thrombectomies, 0.54 angioplasties, and 0.17 surgical revisions. In conclusion, hypoalbuminemia is a strong predictor of the requirement for an early graft intervention. Patients with hypoalbuminemia may require a heightened index of suspicion in monitoring their grafts for evidence of stenosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873874     DOI: 10.1053/ajkd.2000.8269

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

1.  Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2/tissue inhibitor of metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in hemodialysis access.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; Uday M Shergill; Edward B Leof; Debabrata Mukhopadhyay
Journal:  J Vasc Interv Radiol       Date:  2010-06       Impact factor: 3.464

2.  Effect of the time to intervention on the outcome of thrombosed dialysis access grafts managed percutaneously.

Authors:  John David Prologo; Gregory Minwell; Jillian Kent; Ali Pirasteh; David Corn
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients.

Authors:  Timmy Lee; Joyce Qian; Mae Thamer; Michael Allon
Journal:  Am J Nephrol       Date:  2018-12-13       Impact factor: 3.754

4.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

5.  Risk factors associated with patency loss of hemodialysis vascular access within 6 months.

Authors:  Mauricio Monroy-Cuadros; Serdar Yilmaz; Anastasio Salazar-Bañuelos; Christopher Doig
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 8.237

6.  Use of aspirin associates with longer primary patency of hemodialysis grafts.

Authors:  Bradley S Dixon; Gerald J Beck; Laura M Dember; Miguel A Vazquez; Arthur Greenberg; James A Delmez; Michael Allon; Jonathan Himmelfarb; Bo Hu; Tom Greene; Milena K Radeva; Ingemar J Davidson; T Alp Ikizler; Gregory L Braden; Jeffrey H Lawson; James R Cotton; John W Kusek; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

7.  Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

Authors:  Charmaine E Lok; Louise Moist; Brenda R Hemmelgarn; Marcello Tonelli; Miguel A Vazquez; Marc Dorval; Matthew Oliver; Sandra Donnelly; Michael Allon; Kenneth Stanley
Journal:  JAMA       Date:  2012-05-02       Impact factor: 56.272

8.  Wall shear stress measurement using phase contrast magnetic resonance imaging with phase contrast magnetic resonance angiography in arteriovenous polytetrafluoroethylene grafts.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; James F Glockner; Debabrata Mukhopadhyay
Journal:  Angiology       Date:  2009-07-21       Impact factor: 3.619

9.  Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.

Authors:  Jeffrey H Lawson; Marc H Glickman; Marek Ilzecki; Tomasz Jakimowicz; Andrzej Jaroszynski; Eric K Peden; Alison J Pilgrim; Heather L Prichard; Malgorzata Guziewicz; Stanisław Przywara; Jacek Szmidt; Jakub Turek; Wojciech Witkiewicz; Norbert Zapotoczny; Tomasz Zubilewicz; Laura E Niklason
Journal:  Lancet       Date:  2016-05-14       Impact factor: 79.321

10.  Effect of dipyridamole plus aspirin on hemodialysis graft patency.

Authors:  Bradley S Dixon; Gerald J Beck; Miguel A Vazquez; Arthur Greenberg; James A Delmez; Michael Allon; Laura M Dember; Jonathan Himmelfarb; Jennifer J Gassman; Tom Greene; Milena K Radeva; Ingemar J Davidson; T Alp Ikizler; Gregory L Braden; Andrew Z Fenves; James S Kaufman; James R Cotton; Kevin J Martin; James W McNeil; Asif Rahman; Jeffery H Lawson; James F Whiting; Bo Hu; Catherine M Meyers; John W Kusek; Harold I Feldman
Journal:  N Engl J Med       Date:  2009-05-21       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.